From Medscape Dermatology

Coverage from the

American Academy of Dermatology (AAD) Annual Meeting

March 03 - 07, 2017; Orlando, FL

March 03 - 07, 2017 Orlando, FL
  • AAD JAK Inhibitors Show Promise for Alopecia, Eczema, Vitiligo A researcher at the forefront shares promising results from small studies. Clinical trials are in progress and he predicts FDA approval for a JAK inhibitor for alopecia and eczema within 3 years.
  • New Biologic is 'Potential Blockbuster' for Eczema Treatment Dupilumab safely and effectively controls the symptoms of moderate to severe eczema over the long-term, 1-year data show. FDA approval of the biologic is expected soon, the lead investigator reports.
  • New Topical for Mild to Moderate Psoriasis in the Works It's been decades since a new topical option has been available for mild-to-moderate psoriasis, but a new agent shows promise in a phase 3 trial presented as a late-breaker at the AAD Annual Meeting.

Conference News

Popular News From AAD 2016

Medscape Dermatology©  WebMD, LLC

Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.

Previous Coverage